The adverse reactions are described according to the MedDRA system organ class as follows.
Frequencies are defined using the following convention: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1000, <1/100), rare (≥1/10000, <1/1000), very rare (<1/10000), not known (cannot be estimated from the available data).
Immune system disorders: Not known: Hypersensitivity including anaphylaxis.
Metabolism and nutrition disorders: Not known: Increased appetite.
Psychiatric disorders: Not known: Aggression, agitation, hallucination, depression, insomnia, suicidal ideation, nightmare.
Nervous system disorders: Not known: Convulsion, paraesthesia, dizziness, syncope, tremor, diarrhoea.
Ear and labyrinth disorders: Not known: Vertigo.
Eyes disorders: Not known: Visual disturbances, blurred vision, oculogyration.
Cardiac disorders: Not known: Palpitations, tachycardia.
Respiratory, thoracic, and mediastinal disorders: Not known: Dyspnea.
Gastrointestinal disorders: Not known: Nausea, vomiting, diarrhea.
Hepatobiliary disorders: Not known: Hepatitis.
Renal and urinary disorders: Not known: Dysuria, urinary retention.
Skin and subcutaneous tissue disorders: Not known: angioneurotic oedema, fixed drug eruption, pruritus, rash, urticaria.
Musculoskeletal, connective tissues, and bone disorders: Not known: myalgia, arthralgia.
General disorders and administration site conditions: Not known: oedema.
Investigations: Not known: weight increased, abnormal liver function tests.
Description of selected adverse reactions: After levocetirizine discontinuation, pruritus has been reported.
Adverse Drug Reaction: Inform doctors about unexpected reactions after using drugs.